Barclays analyst Luke Sergott raised the firm’s price target on Iqvia (IQV) to $200 from $185 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Early notable gainers among liquid option names on October 1st
- Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
- Lululemon downgraded, Dick’s Sporting upgraded: Wall Street’s top analyst calls
- Iqvia upgraded to Buy from Hold at Jefferies
- Stability and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Leadership Transition